Related Experiment Videos
Tumor volume as a prognostic factor for sarcomatosis
Malcolm M Bilimoria1, Daniel J Holtz, Nadeem Q Mirza
1Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4095, USA.
Cancer
|May 17, 2002
Summary
Disease volume significantly impacts survival in sarcomatosis patients. Low-volume disease offers a better prognosis, while high-volume disease indicates poor survival. Gastrointestinal stromal tumor (GIST) and non-GIST sarcomatosis survival rates are comparable.
Area of Science:
- Oncology
- Surgical Oncology
- Pathology
Background:
- Sarcomatosis, characterized by intraabdominal sarcoma dissemination, presents unclear therapeutic intervention strategies.
- Retrospective analysis of patient data is crucial for understanding survival outcomes in sarcomatosis.
Purpose of the Study:
- To determine overall survival rates in patients diagnosed with sarcomatosis.
- To evaluate the impact of clinicopathologic features on patient survival at two and four years.
Main Methods:
- A retrospective analysis of 51 patients diagnosed with sarcomatosis between 1996 and 1999 was conducted.
- Survival was calculated using Kaplan-Meier analysis, with disease categorized by volume (low/high) and grade (low/intermediate/high).
Main Results:
- Patients with low-volume sarcomatosis had a 2-year survival rate of 82%, compared to 24% for high-volume disease (P = 0.008).
- No significant difference in 2-year survival was observed between gastrointestinal stromal tumors (GIST) and other sarcoma histologies (38% vs. 42%, P = 0.77).
- Tumor grade did not significantly affect survival rates (P = 0.29).
Conclusions:
- Disease volume at diagnosis is a critical factor for stratifying sarcomatosis patients into prognostic subsets.
- Survival rates for GIST and non-GIST sarcomatosis are similar, suggesting a unified approach to treatment considerations.